DelveInsight’s “Achondroplasia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Achondroplasia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Achondroplasia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Achondroplasia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Achondroplasia market.
Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/achondroplasia-market
Some facts of the Achondroplasia Market Report are:
- According to DelveInsight, Achondroplasia market size is expected to grow at a decent CAGR by 2032.
- Leading Achondroplasia companies working in the market are Teva Pharmaceutical Industries, Mylan N.V, Johnsons & Johnsons Services Inc, F. Hoffman-La Roche Ltd., Lilly, Merck, Aurobindo Pharma, Bristol-Myers Squibb Company, GSK plc, Ascendis Pharma A/S, OCUGEN, RIBOMIC, QED Therapeutics, and others.
- Increase in Elderly Population, increasing Adoption of Biosimilars and increased Research Activities are some of the major factors that are driving the Achondroplasia Market growth.
- On March 2024, Ascendis Pharma A/S announced results of a long-term, multi-center, longitudinal, observational study in children with achondroplasia (ACH). The aim is to study height velocity and comorbidities in children with ACH. This is a natural history study and no study medication will be administered.
- On August 2023, QED Therapeutics, Inc. announced results of a Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE.
Achondroplasia Overview
Achondroplasia is a genetic disorder that affects bone growth and development. It is the most common form of dwarfism, accounting for approximately 70% of all cases. People with achondroplasia have short stature, with an average adult height of around four feet. They may also have a larger head size, shorter limbs, and a prominent forehead. Additionally, they may experience spinal stenosis, which can lead to back pain, numbness, and weakness.
Achondroplasia is caused by a mutation in the FGFR3 gene, which provides instructions for making a protein that regulates bone growth. The mutation causes the protein to be overactive, which inhibits bone growth and development.
Achondroplasia is inherited in an autosomal dominant pattern, which means that a person only needs to inherit one copy of the mutated gene from one parent to develop the condition. However, in many cases, achondroplasia occurs sporadically, meaning that there is no family history of the disorder.
Learn more about Achondroplasia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/achondroplasia-market
Achondroplasia Market
The Achondroplasia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Achondroplasia market trends by analyzing the impact of current Achondroplasia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Achondroplasia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Achondroplasia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Achondroplasia market in 7MM is expected to witness a major change in the study period 2019-2032.
Achondroplasia Epidemiology
The Achondroplasia epidemiology section provides insights into the historical and current Achondroplasia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Achondroplasia market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Achondroplasia Epidemiology @ https://www.delveinsight.com/sample-request/achondroplasia-market
Achondroplasia Drugs Uptake
This section focuses on the uptake rate of the potential Achondroplasia drugs recently launched in the Achondroplasia market or expected to be launched in 2019-2032. The analysis covers the Achondroplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Achondroplasia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Achondroplasia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Achondroplasia Pipeline Development Activities
The Achondroplasia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Achondroplasia key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Achondroplasia pipeline development activities @ https://www.delveinsight.com/sample-request/achondroplasia-market
Achondroplasia Therapeutics Assessment
Major key Achondroplasia companies are working proactively in the therapeutics market to develop novel therapies which will drive the Achondroplasia treatment markets in the upcoming years are Teva Pharmaceutical Industries, Mylan N.V, Johnsons & Johnsons Services Inc, F. Hoffman-La Roche Ltd., Lilly, Merck, Aurobindo Pharma, Bristol-Myers Squibb Company, GSK plc, Ascendis Pharma A/S, OCUGEN, RIBOMIC, QED Therapeutics, and others.
Learn more about the emerging Achondroplasia therapies & key companies @ https://www.delveinsight.com/sample-request/achondroplasia-market
Achondroplasia Report Key Insights
1. Achondroplasia Patient Population
2. Achondroplasia Market Size and Trends
3. Key Cross Competition in the Achondroplasia Market
4. Achondroplasia Market Dynamics (Key Drivers and Barriers)
5. Achondroplasia Market Opportunities
6. Achondroplasia Therapeutic Approaches
7. Achondroplasia Pipeline Analysis
8. Achondroplasia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Achondroplasia Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Achondroplasia Competitive Intelligence Analysis
4. Achondroplasia Market Overview at a Glance
5. Achondroplasia Disease Background and Overview
6. Achondroplasia Patient Journey
7. Achondroplasia Epidemiology and Patient Population
8. Achondroplasia Treatment Algorithm, Current Treatment, and Medical Practices
9. Achondroplasia Unmet Needs
10. Key Endpoints of Achondroplasia Treatment
11. Achondroplasia Marketed Products
12. Achondroplasia Emerging Therapies
13. Achondroplasia Seven Major Market Analysis
14. Attribute Analysis
15. Achondroplasia Market Outlook (7 major markets)
16. Achondroplasia Access and Reimbursement Overview
17. KOL Views on the Achondroplasia Market
18. Achondroplasia Market Drivers
19. Achondroplasia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
· On March 2024, Ascendis Pharma A/S announced results of a long-term, multi-center, longitudinal, observational study in children with achondroplasia (ACH). The aim is to study height velocity and comorbidities in children with ACH. This is a natural history study and no study medication will be administered.
· On August 2023, QED Therapeutics, Inc. announced results of a Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting